Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat

Overview

Journal Am J Cardiovasc Drugs

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2024 Dec 31

PMID 39739201

Authors

Jessica Huston

Dontia Orey

Ashish Kumar

Andrew Ashchi

Andrea Ashchi

Jason Berner

Yazan Alkhouri

David Sutton

Wasim Deeb

Mohannad Bisharat

Rebecca F Goldfaden

Affiliations

Soon will be listed here.

Abstract

Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.

References

Jacobs A, Anderson J, Halperin J . The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64(13):1373-84. DOI: 10.1016/j.jacc.2014.06.001. View

Thomopoulos C, Parati G, Zanchetti A . Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016; 34(4):613-22. DOI: 10.1097/HJH.0000000000000881. View

Wang C, Yuan Y, Zheng M, Pan A, Wang M, Zhao M . Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality. J Am Coll Cardiol. 2020; 75(23):2921-2930. DOI: 10.1016/j.jacc.2020.04.038. View

Carey R, Moran A, Whelton P . Treatment of Hypertension: A Review. JAMA. 2022; 328(18):1849-1861. DOI: 10.1001/jama.2022.19590. View

Marrs J . Spironolactone management of resistant hypertension. Ann Pharmacother. 2010; 44(11):1762-9. DOI: 10.1345/aph.1P338. View

Freeman M, Bond M, Murphy B, Hui J, Isaacsohn J . Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2022; 46(1):108-118. PMC: 9747611. DOI: 10.1038/s41440-022-01070-4. View

Booth R, Johnson J, Stockand J . Aldosterone. Adv Physiol Educ. 2002; 26(1-4):8-20. DOI: 10.1152/advan.00051.2001. View

Freeman M, Halvorsen Y, Marshall W, Pater M, Isaacsohn J, Pearce C . Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2022; 388(5):395-405. DOI: 10.1056/NEJMoa2213169. View

Awosika A, Cho Y, Bose U, Omole A, Adabanya U . Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension. Expert Opin Investig Drugs. 2023; 32(11):985-995. DOI: 10.1080/13543784.2023.2276755. View

10.

Freeman M, Halvorsen Y, Bond M, Murphy B, Isaacsohn J . Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function. Clin Pharmacol Drug Dev. 2024; 13(4):410-418. DOI: 10.1002/cpdd.1371. View

11.

Freeman M, Bond M, Murphy B, Hui J, Isaacsohn J . Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects. Am J Cardiovasc Drugs. 2023; 23(3):277-286. PMC: 9930700. DOI: 10.1007/s40256-023-00572-x. View

12.

Dey S, Frishman W, Aronow W . Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension. Cardiol Rev. 2023; . DOI: 10.1097/CRD.0000000000000595. View